217 related articles for article (PubMed ID: 19295595)
1. Cancer: The nuances of therapy.
Ellis LM; Reardon DA
Nature; 2009 Mar; 458(7236):290-2. PubMed ID: 19295595
[No Abstract] [Full Text] [Related]
2. Bevacizumab.
Kazazi-Hyseni F; Beijnen JH; Schellens JH
Oncologist; 2010; 15(8):819-25. PubMed ID: 20688807
[TBL] [Abstract][Full Text] [Related]
3. VEGF inhibition and metastasis: possible implications for antiangiogenic therapy.
English BC; Price DK; Figg WD
Cancer Biol Ther; 2009 Jul; 8(13):1214-25. PubMed ID: 19483467
[No Abstract] [Full Text] [Related]
4. Cancer. Encouraging results for second-generation antiangiogenesis drugs.
Marx J
Science; 2005 May; 308(5726):1248-9. PubMed ID: 15919970
[No Abstract] [Full Text] [Related]
5. How well do angiogenesis inhibitors work? Biomarkers of response prove elusive.
Brower V
J Natl Cancer Inst; 2009 Jun; 101(12):846-7. PubMed ID: 19509354
[No Abstract] [Full Text] [Related]
6. The horizon of antiangiogenic therapy for colorectal cancer.
Olszewski AJ; Grossbard ML; Kozuch PS
Oncology (Williston Park); 2005 Mar; 19(3):297-306; discussion 306, 308, 317-33. PubMed ID: 15828549
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.
Ranieri G; Patruno R; Ruggieri E; Montemurro S; Valerio P; Ribatti D
Curr Med Chem; 2006; 13(16):1845-57. PubMed ID: 16842197
[TBL] [Abstract][Full Text] [Related]
8. [Treatment with antiangiogenic drugs].
Saijo N
Nihon Rinsho; 2010 Jun; 68(6):1007-13. PubMed ID: 20535948
[TBL] [Abstract][Full Text] [Related]
9. Targeted drugs for metastatic renal cell carcinoma.
Motzer RJ; Basch E
Lancet; 2007 Dec; 370(9605):2071-3. PubMed ID: 18156012
[No Abstract] [Full Text] [Related]
10. Targeted therapies: bevacizumab--has it reached its final resting place?
Kerr DJ; Young AM
Nat Rev Clin Oncol; 2011 Mar; 8(4):195-6. PubMed ID: 21386819
[No Abstract] [Full Text] [Related]
11. [Angiogenesis inhibitors in cancer therapy. Bevacizumab against colon carcinoma].
Fieth C; Kebig A; Mohr K
Pharm Unserer Zeit; 2007; 36(6):442-5. PubMed ID: 17957688
[TBL] [Abstract][Full Text] [Related]
12. [Bevacizumab. Progress in cancer therapy by antiangiogenesis].
Krämer I; Lipp HP
Med Monatsschr Pharm; 2006 Jul; 29(7):249-54; quiz 255-6. PubMed ID: 16866078
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapy of colorectal cancer: clinical experience with bevacizumab.
Fernando NH; Hurwitz HI
Oncologist; 2004; 9 Suppl 1():11-8. PubMed ID: 15178811
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor pathway.
Maitland ML; Lou XJ; Ramirez J; Desai AA; Berlin DS; McLeod HL; Weichselbaum RR; Ratain MJ; Altman RB; Klein TE
Pharmacogenet Genomics; 2010 May; 20(5):346-9. PubMed ID: 20124951
[No Abstract] [Full Text] [Related]
15. Bevacizumab: a review of its use in metastatic colorectal cancer.
McCormack PL; Keam SJ
Drugs; 2008; 68(4):487-506. PubMed ID: 18318567
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab, sunitinib: osteonecrosis of the jaw.
Prescrire Int; 2011 Jun; 20(117):155. PubMed ID: 21682016
[No Abstract] [Full Text] [Related]
17. Bevacizumab for advanced breast cancer.
Traina TA; Rugo HS; Dickler M
Hematol Oncol Clin North Am; 2007 Apr; 21(2):303-19. PubMed ID: 17512451
[TBL] [Abstract][Full Text] [Related]
18. Biological mechanisms of bevacizumab-associated adverse events.
Higa GM; Abraham J
Expert Rev Anticancer Ther; 2009 Jul; 9(7):999-1007. PubMed ID: 19589038
[TBL] [Abstract][Full Text] [Related]
19. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.
Ferrara N; Hillan KJ; Gerber HP; Novotny W
Nat Rev Drug Discov; 2004 May; 3(5):391-400. PubMed ID: 15136787
[No Abstract] [Full Text] [Related]
20. Taming vessels to treat cancer.
Jain RK
Sci Am; 2008 Jan; 298(1):56-63. PubMed ID: 18225696
[No Abstract] [Full Text] [Related]
[Next] [New Search]
